We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2
Read MoreHide Full Article
Avenue Therapeutics, Inc. (ATXI - Free Report) reported a loss of 11 cents per share in the second quarter of 2020, wider than the Zacks Consensus Estimate of a loss of 10 cents. The loss was, however, narrower than the year-ago quarter’s loss of 43 cents.
Avenue Therapeutics’ stock has risen 10.3% so far this year against the industry’s decline of 6.3%.
It is a clinical-stage biopharmaceutical company developing products, principally for use in the acute/intensive care hospital setting. The company’s sole pipeline candidate, intravenous tramadol, is under review for the treatment of moderate to moderately severe postoperative pain.
The company has completed two late-stage studies, evaluating tramadol in patients with moderate-to-severe pain following bunionectomy or abdominoplasty, in the last two years and submitted a new drug application in December 2019. The NDA was accepted by the FDA in February and a decision is expected on Oct 10, 2020.
Research and development expenses for the second quarter of 2020 were $1.2 million compared with$6.4 million in the year-ago quarter. This decrease was mainly attributable to the completion of the abdominoplasty and safety studies in 2019.
General and administrative expenses for the second quarter of 2020 were flat year over year at approximately $0.7 million.
As of Jun 30, 2020, Avenue’s cash and cash equivalents were $5.3 million, compared to $6.6 million at March 31, 2020, a decrease of $1.3 million for the quarter.
Avenue Therapeutics, Inc. Price, Consensus and EPS Surprise
Pacira’searnings per share estimates have increased to $2.06 from $1.78 for 2020 and from $3.12 to $3.62 for 2021 in the past 60 days.
BioLineRx’s loss per share estimates have narrowed from $2.24 to $1.95 for 2020 and from $2.88 to $1.44 for 2021 in the past 60 days.
Eisai’s earnings per share estimates have increased from $2.28 to $2.36 for 2020 and from $2.262 to $2.30 for 2021 in the past 60 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2
Avenue Therapeutics, Inc. (ATXI - Free Report) reported a loss of 11 cents per share in the second quarter of 2020, wider than the Zacks Consensus Estimate of a loss of 10 cents. The loss was, however, narrower than the year-ago quarter’s loss of 43 cents.
Avenue Therapeutics’ stock has risen 10.3% so far this year against the industry’s decline of 6.3%.
It is a clinical-stage biopharmaceutical company developing products, principally for use in the acute/intensive care hospital setting. The company’s sole pipeline candidate, intravenous tramadol, is under review for the treatment of moderate to moderately severe postoperative pain.
The company has completed two late-stage studies, evaluating tramadol in patients with moderate-to-severe pain following bunionectomy or abdominoplasty, in the last two years and submitted a new drug application in December 2019. The NDA was accepted by the FDA in February and a decision is expected on Oct 10, 2020.
Research and development expenses for the second quarter of 2020 were $1.2 million compared with$6.4 million in the year-ago quarter. This decrease was mainly attributable to the completion of the abdominoplasty and safety studies in 2019.
General and administrative expenses for the second quarter of 2020 were flat year over year at approximately $0.7 million.
As of Jun 30, 2020, Avenue’s cash and cash equivalents were $5.3 million, compared to $6.6 million at March 31, 2020, a decrease of $1.3 million for the quarter.
Avenue Therapeutics, Inc. Price, Consensus and EPS Surprise
Avenue Therapeutics, Inc. price-consensus-eps-surprise-chart | Avenue Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Avenue Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the sector include PaciraBioSpecificsInc. (PCRX - Free Report) , BioLineRx Ltd. and Eisai Co. . While Pacira sports a Zacks Rank #1 (Strong Buy), BioLineRx and Eisai carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Pacira’searnings per share estimates have increased to $2.06 from $1.78 for 2020 and from $3.12 to $3.62 for 2021 in the past 60 days.
BioLineRx’s loss per share estimates have narrowed from $2.24 to $1.95 for 2020 and from $2.88 to $1.44 for 2021 in the past 60 days.
Eisai’s earnings per share estimates have increased from $2.28 to $2.36 for 2020 and from $2.262 to $2.30 for 2021 in the past 60 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>